Friday, 19 Oct 2018

You are here

JAK Inhibition in Autoinflammatory Syndromes Interferonopathies

While many autoinflammatory syndromes are driven and managed with select inhibition of IL-1, IL-18 or IL-6, a subset are driven by type I interferon and are referred to as interferonopathies. These monogenic IFN–mediated disorders present in infancy with fevers, systemic inflammation, an IFN response gene signature, inflammatory organ damage, and high mortality.

Now researchers from the NIH have demonstrated that the use of the JAK inhibitor baricitinib, with IFN-blocking activity in vitro, leads to clinical disease improvement.

Researchers treated 18 patients, between 2011 and 2017, who were diagnosed with CANDLE (10 patients; chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures), 4 patients with SAVI (stimulator of IFN genes–associated [STING-associated] vasculopathy with onset in infancy), and 4 patients with other interferonopathies were enrolled in an expanded access program. 

Treatment for a mean of 3 years (1.5–4.9 years) led to symptom symptom score decreases from 1.3 (interquartile range [IQR], 0.93–1.78) to 0.25 (IQR, 0.1–0.63) (P < 0.0001) and reduced steroid use (14 patients) from 0.44 mg/kg/day to 0.11 mg/kg/day, and their IFN biomarkers decreased. Among the 10 CANDLE patients half achieved lasting clinical remission.

Three patients discontinued treatment because of lack of efficacy; 2 of these had genetically undefined conditions.

The most common adverse events were upper respiratory infections, gastroenteritis, and BK viruria and viremia.

These patients are usually poorly responsive to DMARDs or biologics targeting IL-1, TNF, and IL-6., In these studies the JAK1,2 inhibitor, baricitinib, improved inflammatory and IFN biomarkers in patients with the very rare disorders CANDLE, SAVI and other interferonopathies. 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

IL-6 for Adult Still's: A New Option?

Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met, Japanese researchers reported.

Unproven But Profitable Stem Cell Clinics

Stem cell clinics are popular and proliferating as they are largely a cash business and fall outside of FDA regulatory control. In lieu of scientific proof, most advocates use patient testimonials and the placebo effect to back up their claims.

Out of Pocket Costs for Biosimilars - No Savings So Far

JAMA has published an analysis showing that under Medicare Part D, RA biosimilar infliximab-dyyb was only moderately less expensive (18% less) than the biologic infliximab and, owing to differences in gap discounts, the out of pocket costs for the biosimilar was nearly $1700 more than infliximab in 2017.

Cutting Oral JAK 1/2 Inhibitor Dose an Option in RA

Many patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib (Olumiant) treatment were able to reduce their daily dose from 4 mg to 2 mg and maintain their response, a double-blind substudy of a long-term extension trial found.

Tocilizumab Equals other Biologics in Cardiovascular Risk

An odd side effect of several new agents is the risk of hyperlipidemia. While this has been seen with tocilizumab (TCZ), there does not appear to be a resultant risk of cardiovascular (CV) events. A study of claims data compared CV risk in rheumatoid arthritis (RA) patients receiving TOC (an IL6 receptor antagonists) and other biologics and found no differences with regard to CV outcomes.